title: Post-kala-azar dermal Leishmaniasis in two different clinical contexts.
abstract: In Brazil, visceral Leishmaniasis is caused by Leishmania chagasi. The development of cutaneous lesions in visceral leishmaniasis patients has been described in two different clinical contexts. Patients with compromised immunity can develop skin lesions as a direct consequence of a current visceral disease. Equally, patients with a history of kala-azar and progressive, immune improvement occasionally develop skin lesions as a consequence of immune reconstitution inflammatory syndrome. These cases manifest in similar fashion to the classic form of post-kala-azar dermal Leishmaniasis. We describe different cases that exemplify these two clinical presentations.
authors: Universidade de Pernambuco, Recife, PE, BR.
authors: Daniel Holanda
authors: DH
authors: Barroso
authors: Universidade Federal de Pernambuco, Recife, PE, BR.
authors: Claúdia Elise Ferraz
authors: CE
authors: Silva
authors: Universidade de Pernambuco, Recife, PE, BR.
authors: Ana Carolina Depes
authors: AC
authors: Perdigao e Vasconcelos
authors: Universidade de Pernambuco, Recife, PE, BR.
authors: Silvana Maria de Morais
authors: SM
authors: Cavalcanti
authors: Fundação Oswaldo Cruz, Recife, PE, BR.
authors: Maria Edileuza Felinto de
authors: ME
authors: Brito
authors: Universidade de Pernambuco, Recife, PE, BR.
authors: Angela Cristina Rapela
authors: AC
authors: Medeiros
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000276:immunology*; D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy / Q000276:immunology*; D007898:Leishmaniasis, Visceral / Q000188:drug therapy / Q000276:immunology*; D008297:Male
chemical_list: D000981:Antiprotozoal Agents; D000666:Amphotericin B